Compositions and methods for specific regulation of pyruvate dehydrogenase kinase
A peptide composition is provi'deo! which specifically inhibits the ability of δ protein kinase C (δPKC) to phosphor/late pyruvate dehydrogenase kinase (PDK) under ischemic conditions. The peptide composition is useful for treating or reducing tissue damage resulting from ischemia and/or reperfusion.
1. A pharmaceutical composition comprising a δPKC-selective modulatory peptide 5 to 20 amino acids in length comprising a contiguous core sequence of 5 amino acid residues and further comprising a first cysteine residue located at the N-terminal or C-terminal end of the modulatory peptide,
wherein the contiguous core sequence is at least 60% identical to SEQ ID NO:1,
and a pharmaceutically acceptable excipient.
2. The pharmaceutical composition of claim 1 , wherein the modulatory peptide is 5 to 15 amino acid residues in length.
3. The composition of claim 2 , wherein the contiguous core sequence is at least 80% identical to SEQ ID NO:1.
4. The composition of claim 2 , wherein the contiguous core sequence is identical to SEQ ID NO:1.
5. The pharmaceutical composition of claim 1 , wherein the first cysteine residue is linked to a carrier peptide, wherein the carrier peptide comprises a second cysteine residue at the N-terminal or C-terminal end of the carrier peptide.
6. The composition of claim 5 , wherein the modulatory peptide consists of SEQ ID NO:53 and the carrier peptide consists of SEQ ID NO:52.
7. The composition of claim 1 , wherein the modulatory peptide is 6-8 amino acids in length.
8. The composition of claim 7 , wherein the contiguous core sequence is at least 80% identical to SEQ ID NO:1.
9. A method for reducing ischemic injury to cardiac tissue comprising administering to a subject in need thereof a δPKC-selective modulatory peptide, wherein the modulatory peptide is 5 to 20 amino acids in length, comprises a contiguous core sequence of 5 amino acid residues wherein the contiguous core sequence is at least 60% identical to SEQ ID NO:1, and further comprises a first cysteine residue located at the N-terminal or C-terminal end of the modulatory peptide.
10. The method of claim 9 , wherein the subject is suffering from cardiovascular disease, cardiac ischemia, cardiac ischemia/reperfusion injury, myocardial infarction, chronic stable angina, or acute coronary syndrome.
11. The method of claim 9 , wherein the modulatory peptide is 5 to 15 amino acid residues in length.
12. The method of claim 11 , wherein the contiguous core sequence is at least 80% identical to SEQ ID NO:1.
13. The method of claim 11 , wherein the contiguous core sequence is identical to SEQ ID NO:1.
14. The method of claim 9 , wherein the first cysteine residue is linked to a carrier peptide, wherein the carrier peptide comprises a second cysteine residue at the N-terminal or C-terminal end of the carrier peptide.
15. The method of claim 14 , wherein the modulatory peptide consists of SEQ ID NO:53 and the carrier peptide consists of SEQ ID NO:52.
16. The method of claim 9 , wherein the modulatory peptide is 6-8 amino acids in length.
17. The method of claim 16 , wherein the contiguous core sequence is at least 80% identical to SEQ ID NO:1.